Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DUT | P33316 | 1/20 | 0.42 |
| ▸ | FFAR1 | O14842 | 4/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.40 |
| ▸ | GPR88 | Q9GZN0 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | ACACA | Q13085 | 2/20 | 0.39 |
| ▸ | ACACB | O00763 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2205493 | 1.00 | DUT (0.42) | DUTFFAR1L3MBTL1GRM2GPR88 | |
| SCHEMBL2209619 | 0.99 | DUT (0.41) | DUTFFAR1L3MBTL1GRM2 | |
| SCHEMBL4085382 | 0.99 | DUT (0.41) | DUTFFAR1L3MBTL1GRM2 | |
| SCHEMBL2235433 | 0.87 | MAOA (0.39) | DUTFFAR1KMT2A | |
| SCHEMBL2235448 | 0.87 | MAOA (0.39) | DUTFFAR1KMT2A | |
| SCHEMBL2235442 | 0.87 | MAOA (0.39) | DUTFFAR1KMT2A | |
| SCHEMBL2207489 | 0.84 | DUT (0.41) | DUTFFAR1L3MBTL1GRM2 | |
| SCHEMBL21100523 | 0.83 | DUT (0.40) | DUTFFAR1ACACAACACB | |
| SCHEMBL4423217 | 0.83 | SIRT2 (0.39) | DUTFFAR1L3MBTL1GRM2 | |
| SCHEMBL2207890 | 0.82 | PDE4B (0.43) | FFAR1GRM2GPR88 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10188615-B2 | Alkoxy compounds for disease treatment | ACUCELA INC. (US) | 2019-01-29 | — | — | US | disclosed |
| US-20180177746-A1 | ALKOXY COMPOUNDS FOR DISEASE TREATMENT | ACUCELA INC. | 2018-06-28 | — | — | US | disclosed |
| US-20150239836-A1 | ALKOXY COMPOUNDS FOR DISEASE TREATMENT | ACUCELA INC. | 2015-08-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150239836-A1 | ALKOXY COMPOUNDS FOR DISEASE TREATMENT | ALDH1A2, CLN6, AGER | DUT 3010/4885FFAR1 582/4885L3MBTL1 2398/4885 |
| US-10188615-B2 | Alkoxy compounds for disease treatment | ALDH1A2, CLN6, AGER | DUT 3010/4885FFAR1 582/4885L3MBTL1 2398/4885 |
| US-20180177746-A1 | ALKOXY COMPOUNDS FOR DISEASE TREATMENT | ALDH1A2, CLN6, AGER | DUT 3010/4885FFAR1 582/4885L3MBTL1 2398/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.